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Background:  The epidemiology of adverse drug events (ADEs) and medication 
errors has received little evaluation outside the U.S. and Europe, and 
extrapolating from these data might not be valid, especially regarding selecting 
and prioritizing solutions.   
Objective:  To assess the incidence and preventability of ADEs and medication 
errors in Japan.   
Design:  The Japan Adverse Drug Events (JADE) study was a prospective 
cohort study.   
Patients:  A cohort of 3,459 adults admitted to a stratified random sample of 7 
medical and 8 surgical wards and 3 intensive care units in three tertiary care 
hospitals over 6 months.   
Main Measures:  We measured ADE and medication error rates from daily 
reviews of charts, laboratories, incident reports, and prescription queries by 
on-site reviewers; presence of a signal was considered an incident.  Two 
independent physicians reviewed incidents to determine whether they were 
ADEs or medication errors, and to assess severity and preventability.   
Key Results:  We identified 1,010 ADEs and 514 medication errors (incidence: 
17.0 and 8.7 per 1000 patient-days, respectively) during the study period.  
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Among ADEs, 1.6%, 4.9% and 33% were fatal, life-threatening and serious, 
respectively.  Among ADEs, 14% were preventable.  The rate per admission 
was 29 per 100 admissions, higher than in U.S. studies because associated with 
of the long length of hospital stay in Japan (mean, 17 days).  
Conclusions:  The epidemiology and nature of ADEs and medication errors in 
Japan were similar to other countries, although more frequent per admission.  
Solutions that worked in these countries might thus improve medication safety in 





Injuries due to medications, referred to as adverse drug events 
(ADEs),1 represent the most frequent cause of injuries due to medical care in 
hospitals in developed countries.2, 3  Studies have found that 6.5% of adult 
inpatients,4 27.4% of adult outpatients,5 and 2.3% of pediatric inpatients 
developed ADEs,6 while a meta-analysis on adult inpatients found a rate of 6.7% 
for adverse drug reactions. 7  The consequences of ADEs range from relatively 
minor symptoms such as a rash to death,1, 4 and ADEs also result in important 
consequences including hospital admission, prolonged hospital stay and 
additional resource utilization.8  Similar to other injuries due to medical care, 
ADEs can be associated with errors and preventable, or can be non-preventable.  
They can occur at any stage in the medication use process, including ordering, 
transcribing, dispensing, administering and monitoring.1  Medication errors are 
any error in the medication process; they are much more common than ADEs 
with one study finding them in 5.3% of medication orders, although they often do 
not result in harm.4   
The epidemiology and nature of ADEs and medication errors in 
hospitals have been described in detail in some Western countries, but almost all 
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the available data come from these nations.3  Many of the studies from outside 
the U.S. which addressed this issue were from many years ago.9-11  Without 
such basic data from all parts of the world, the effectiveness of various solutions 
attested in some Western countries cannot necessarily be extrapolated to local 
settings worldwide.12  In addition, patient safety has become a global concern.  
The World Health Organization thus launched the World Alliance for Patient 
Safety to investigate the impact of patient safety issues.13  Thus, investigating 
the epidemiology and nature of ADEs and medication errors in local settings is 
essential for patient safety from both the local and global perspectives.   
In particular, to have more information from outside the Western 
countries would be very helpful for understanding the differences by nation and 
region, as well as to suggest what interventions may be most helpful.  To 
address these issues, we therefore conducted the Japan Adverse Drug Events 
(JADE) Study, a prospective cohort study to estimate the incidence and 
characteristics of ADEs and medication errors in Japan.   
 
Methods 
Study design and patient population 
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The JADE Study was a prospective cohort study involving three 
urban tertiary care hospitals in Japan.  Two hospitals had electronic medical 
records and one did not, but none had decision support systems for prescribing 
or other clinical domains.  All were teaching hospitals and resident physicians 
defined as having <3 years of training after obtaining a license were in charge of 
some of the patients under the supervision of attending physicians, while 
attending physicians directly cared for other patients without resident physicians.  
The total number of beds among the three hospitals was 2,224, and they were 
spread among 26 adult medical wards, 30 surgical wards, and 3 intensive care 
units (ICUs).  The hospitals also included obstetrics/gynecology, and pediatrics 
wards but we excluded these wards because they have low rates of medication 
use.  The 56 medical and surgical wards were stratified according to hospital 
and whether they were medical or surgical wards, and study wards were 
randomly selected within a stratum using a random number generator.  We, 
thus included 7 medical and 8 surgical wards as well as all 3 ICUs so that the 
study design and sample size were similar to a previous report.4   
We included all adult patients aged ≥15 years who were admitted to 
any of the 18 study wards over a 6-month period from January through June 
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2004.  The main units of evaluation were patient-day and admission number.  
The institutional review boards of three participating hospitals and Kyoto 
University Graduate School of Medicine approved the study.   
 
Data collection and classification 
Based on the reported methods,1 trained nurses or nursing students 
placed at each participating hospital reviewed all charts daily on weekdays, 
along with laboratories, incident reports, and prescription queries.  They also 
collected the characteristics of the patients in the cohort.   
The primary outcome of the study was the ADE, defined as an injury 
due to a medication.  For example, cough after receiving 
angiotensin-converting enzyme (ACE) inhibitors without other reasons is 
considered an ADE.  We also identified medication errors, and we refer to 
ADEs with medication errors as preventable ADEs, and those without 
medication errors as non-preventable ADEs.  Some ADEs are associated with 
medication errors and they can be prevented if such errors were intercepted.  
Medication errors could occur at any step of the medication use process.  
Medication errors may or may not cause ADEs.  For example, cough due to an 
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ACE inhibitor in a patient without a history of ACE inhibitor-induced cough would 
not be the result of a medication error, but it would be if the patient had a history 
of such cough.  Minor errors that had little or no potential for harm were not 
considered potential ADEs but as medication errors (for example, a dose of 
noncritical medication such as docusate being administered several hours late).  
An incident that had potential for harm was considered both a medication error 
and a potential ADE (for example, a dose of critical medication such as an 
intravenous antibiotic not being administered).  A potential ADE was a 
medication error with the potential to cause an injury but which did not actually 
do so, either because of specific circumstances, chance, or because the error 
was intercepted and corrected (for example, an order was written for an 
overdose of medication but the error was intercepted by the pharmacist).   
Two independent physician reviewers evaluated all incidents and 
classified them according to whether they were ADEs or medication errors, as 
well as to their severity and preventability.  If a medication error was found, then 
the type of error and stage in the process at which it occurred were also 
classified.  Reviewers considered ADEs as preventable if they were due to an 
error or were ameliorable by any means available.  Categories of severity were 
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fatal, life-threatening, serious, and significant.1  Briefly, fatal ADEs resulted in 
death; life-threatening ADEs caused such issues as transfer to ICU or 
anaphylactic shock; serious ADEs included gastrointestinal bleeding, altered 
mental status, excessive sedation, increased creatinine, or a decrease in blood 
pressure; and significant ADEs included for example cases with rash, diarrhea or 
nausea.  The stages of the medication use process were: ordering by 
physicians, transcription by nurses, dispensing by pharmacists, administration 
by nurses or patients themselves, and monitoring by physicians or other health 
professionals.  When disagreement affected classification of an event, the 
reviewers reached consensus through discussion.   
Inter-rater reliabilities were assessed using kappa statistics.  The 
kappa scores regarding presence of an ADE between reviewers were 0.75 (ADE 
vs potential ADE or exclude) and 0.77 (Exclude vs ADE or potential ADE).  The 
kappa for preventability was 0.86 (preventable vs non-preventable), while 
kappas for severity were 0.31 (life-threatening vs serious or significant) and 0.64 
(significant vs serious or life-threatening).  These values were similar to a 





Incidence per 1000 patient-days, crude rates per 100 admissions and 
their 95% confidence intervals [CIs] were calculated as a whole and by ward 
type (medical, surgical, or ICU).  To extrapolate to total annual rates in the 3 
hospitals, we assumed admissions to all wards at these hospitals excluding 
obstetrics/gynecology and pediatrics based on data from the previous year.  
The observed rate for each ward type was applied to all wards of that type. 
Continuous variables are presented as mean ± standard deviation 
(SD) or median (interquartile range), and categorical variables are shown as 
numbers and percentages.  We used the logistic regression models to assess 
the relationships between potential risk factors and ADEs or medication errors.  
The potential risk factors included were elderly (≥65 years), gender, ward type 
(admitted to ICU, medical or surgical ward), whether the physician in charge was 
a resident, admission pathway (scheduled, emergency, transferred from other 
ward), history of allergy, and the number of medication use on admission.  We 





During the study period, there were 3,459 admissions with 59,383 
patient-days on the study wards.  Based on hospital administrative data, 27,156 
admissions per year were predicted at the 3 hospitals excluding the 
obstetrics/gynecology and pediatric wards, and 13% of all patients were 
sampled in this study.  Among the 3,459 patients, 1,958 (57%) were male and 
the mean age was 66 (SD 17) years; 62% were aged ≥65 years.  The median 
hospital stay was 10 (interquartile range 4-19) days.  The medical and surgical 
wards and the ICUs admitted 1,531 (44%), 1,469 (42%), and 459 (13%) patients, 
respectively.  The median number of medications on admission was 4 (range 
0-17).   
 
Adverse drug events 
The on-site reviewers identified 4,581 incidents during the study 
period.  Among these incidents, reviewers judged that there were 1,010 ADEs 
in 726 patients, for an incidence of 17.0 [95%CI 16.0-18.1] per 1000 patient-days 
and a crude rate per 100 admissions of 29.2 [95%CI 27.7-30.7].  Based on 
these data and information from the 3 hospitals, 8,000 ADEs are estimated to 
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occur annually among the 3 hospitals.  The incidence was higher in ICUs, with 
30.7 ADEs per 1000 patient-days, whereas the crude rate was higher in medical 
wards, with 32.9 events per 100 admissions (Table 1).  The median hospital 
stay from admission to ADE was 7 (interquartile range 3-14) days.   
Fourteen patients suffered fatal ADEs during the study; in this group, 
two patients suffered two ADEs (Table 2).  Fatal and life-threatening ADEs 
accounted for 1.6% and 4.9% of all ADEs, respectively.  Ten of 14 patients with 
fatal ADEs died from antibiotics-associated ADEs.  Sixty percent of ADEs were 
significant and few caused permanent disability (Table 2).   
Antibiotics accounted for one-third of all ADEs and thus represented 
the most frequent drug class associated with ADEs.  Sedatives, non-steroidal 
antiinflammatory drugs (NSAIDs) and laxatives caused 9%, 8%, and 7% of 
ADEs, respectively.  Sedatives, NSAIDs, and electrolytes were the most 
frequent drug classes involved in preventable ADEs, whereas antibiotics were 
the class most frequently associated with non-preventable ADEs (Table 3).   
Several factors were associated with ADEs (Table 4).  Those aged 
≥65 years had a significantly higher rate of ADEs than younger patients.  Those 
admitted to ICUs were at lower risk for ADEs; however, having a resident 
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physician as the doctor in charge increased risk.  The history of allergy was a 
correlated with ADE risk.   
 
Medication errors and potential adverse drug events 
This study identified 514 medication errors among 433 patients 
(incidence: 8.7 [95%CI 7.9-9.4] per 1000 patient-days) and a crude rate of 14.9 
[95%CI 13.7-16.0] per 100 admissions.  Based on a similar calculation for 
ADEs, an estimated 4,052 medication errors occur annually among the 3 
hospitals.  The incidence was higher in ICUs with 17.0 medication errors per 
1000 patient-days and the crude rate was higher in surgical wards with 16.4 
events per 100 admissions.  The median hospital stay from admission to 
medication error was 3 (interquartile range 1-10) days.  Among the 514 
medication errors, 141 actually resulted in ADEs and were preventable ADEs 
whereas 339 had the potential to cause harm (Figure 1).  The incidence of 
preventable ADEs and non-preventable ADEs were 2.4 [95%CI 2.0-2.8] and 
14.6 [95%CI 13.7-15.6] per 1000 patient-days, respectively.  Thus, 14% of 
ADEs were considered preventable.  The incidence of potential ADEs was thus 
5.7 [95%CI 5.1-6.3] per 1000 patient-days.  Thirty-four were errors but not 
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considered potential ADEs because of no risk of harm to patients.  Three of 10 
potential ADEs (98 cases) were intercepted before a drug was administered and 
were thus intercepted potential ADEs.  Of the rest, the patient did not actually 
take the drug without need in 70 cases, or took the drug but no consequences 
were identified in 171 cases.  These 241 cases were non-intercepted potential 
ADEs.  The incidence of intercepted and non-intercepted potential ADEs were 
1.7 [95%CI 1.3-2.0] and 4.1 [95%CI 3.5-4.6] per 1000 patient-days, respectively.   
Two-thirds of preventable and potential ADEs that were associated 
with medication errors occurred at the ordering stage (Table 5).  Among them, 
half of the preventable ADEs arose at the monitoring stage, but most potential 
ADEs occurred at the ordering stage (Table 5).  Intercepted potential ADEs 
occurred at earlier stages whereas non-intercepted and actual but preventable 
ADEs occurred at later stages.  Factors associated with medication errors 
included being admitted to a surgical ward and having a resident physician as 
the doctor in charge (Table 4).  Those transferred from other wards, prescribed 
more medication on admission, and with history of allergy also had higher risk of 





The JADE study used the same methodology as that described by 
Bates et al in 1995.4  The incidence of ADEs in the present study was 17.0 per 
1000 patient-days, which was fairly similar to the 11.5 that reported by Bates et 
al.  However, the rate per admission differed substantially between the present 
study and that of 1995 Bates study--29 vs. 6 ADEs per 100 admissions.  This 
gap was primarily due to the large difference in the mean length of hospital stay 
between Japan and the U.S., which was 17 vs. 5 days, respectively.  However, 
our results were consistent with another recent epidemiological report on 
inpatients from the U.S. which found an incidence of 15 ADEs per 100 
admissions.14  Hospitals can be dangerous places, and shortening stays in 
Japanese hospitals could potentially reduce the frequency of ADEs.  The 
reasons for the differences in length of stay are largely cultural and relate in part 
to patient expectations.15, 16  Physicians and even patients, can determine the 
timing of discharge more freely in Japan compared to the U.S.16, 17  In addition, 
the reimbursement from government-run health insurance is generally based on 
the length of hospital stay, and because of shortages of ambulatory care, the 
physicians, patients, and their families are all inclined to keep patients in hospital 
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longer.17  Thus, the findings that longer hospital stay is substantially associated 
with ADEs represents one incentive to shorten the length of hospital stay, though 
many factors are clearly involved.   
We found many common epidemiological characteristics of ADEs 
and medication errors between Japan and the U.S., including the severity and 
drug class of ADEs, ward type, stage of medication errors, and proportion of 
interception of potential ADEs.  For example, nearly half of all medication errors 
occurred at the ordering stage (66% in Japan and 49% in the U.S.), followed by 
the administration or monitoring stages.  Both studies also found that almost 
half of potential ADEs were intercepted before the drugs reached patients.  
These findings support the notion that ADEs and medication errors may 
represent similar processes despite major differences in medical systems and 
cultures, although the situation might also be quite different especially in settings 
such as developing countries.   
We assessed the frequency of ADEs and medication errors in daily 
practice in hospitals in Japan and found that they occur often and cause 
substantial harm.  Based on these data, healthcare professionals, policy 
makers, patients, and even the general population should be aware of the risk of 
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medical care and drugs.  Because the epidemiology and characteristics of 
ADEs and medication errors were quite similar despite differences in healthcare 
systems, extrapolation from state-of-art solutions in the U.S. such as 
computerized physician order entry, bar-coding, and having pharmacists round 
with teams in the intensive care units should be evaluated in Japan and perhaps 
other developed countries, with public support and investment.18, 19   
In addition, we identified several specific factors that were associated 
with ADEs in Japan.  Older patients, those in ICUs, those transferred from other 
wards, and those with a history of allergy as well as those cared for by resident 
physicians were all at higher risk for ADEs.  Thus, solutions targeting these 
groups could be especially effective locally in Japan.  Transition from other 
wards was considered a particularly high risk for any kind of harm from medical 
care and a top priority of patient safety in developed countries.13  Although 
regulating work hours in the U.S. does not apparently reduce ADEs,20 other 
interventions for workplace and education for resident physicians could also be a 
focus of research.   
Our study has several limitations.  First, we analyzed data 
generated by the random sampling of wards from only 3 urban tertiary care 
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hospitals.  Therefore, our results might not be representative of Japanese 
inpatients in general.  Also, healthcare providers might have been aware of this 
prospective cohort study, but a Hawthorne effect if present would suggest that 
our estimates are if anything conservative.  Similarly, some ADEs may not have 
been noted in the charts and may thus have been missed, which would also 
make our estimates a lower bound.  In addition, data collection was conducted 
in 2004, so that the current situation might be different.  The main outcomes of 
our study were ADEs and medication errors, which required implicit judgment.  
However, the interrater reliability levels were reasonable and more robust 
alternatives to measure ADEs and medication errors have not yet been 
developed,1 so that the approach we used is the standard one.   
In conclusion, we showed that ADEs and medication errors were 
quite frequent in Japanese acute care hospitals, and that they were of a similar 
nature to those arising in the Western countries.  The proportion of preventable 
ADEs and of potential ADEs with medication errors among all incidents was 
significant, and most of the errors occurred at the ordering, administration and 
monitoring stages.  Interventions to support healthcare providers during 
ordering and administering to patients may improve drug safety among hospital 
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inpatients, as could reducing length of stay.  Future studies should assess the 
epidemiology in other settings in other countries, and the effectiveness of 
interventions that have been successful in the Western countries such as 
information technologies should be tested in other nations.   
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Table 1. Incidence of adverse drug events 






Medicine 1531 25734 504 19.6 17.9-21.3 32.9 30.6-35.3 4148 
Surgery 1469 30419 407 13.4 12.1-14.7 27.7 25.4-30.0 3218 
ICU 459 3230 99 30.7 24.6-36.7 21.6 17.8-25.3 634 
ADE, adverse drug event; ICU, intensive care unit; CI, confidence interval; *per 
1000 patient-days; †per 100 admissions; ‡Extrapolated from number of 
ADEs and information from 3 hospitals.  
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Table 2. Severity of adverse drug events 
Severity n (patients) Rate (%) 95% CI 
Death 16 (14) 1.6 0.8-2.4 
Life-threatening 49 (46) 4.9 3.5-6.2 
Serious 330 (272) 32.7 29.8-35.6 
Significant 615 (521) 60.9 57.9-63.9 
CI, confidence interval. 
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ADEs, n (%) 
(n=241) 
Antibiotics 365 (36) 19 (13) 346 (40) 17 (5.0) 8 (8.2) 9 (3.7) 
Antitumor 
agents 
26 (2.6) 3 (2.1) 23 (2.7) 1 (0.3) 0 (0) 1 (0.4) 
Diuretics 20 (2.0) 4 (2.8) 16 (1.8) 11 (3.2) 3 (3.1) 8 (3.3) 
Antihypertensiv
es 
52 (5.1) 9 (6.4) 43 (5.0) 40 (12) 12 (12) 28 (12) 
Antiarrhythmics 2 (0.2) 0 (0) 2 (0.2) 3 (0.9) 3 (3.1) 0 (0) 
Cardiovascular 14 (1.4) 2 (1.4) 12 (1.4) 7 (2.1) 4 (4.1) 3 (1.2) 
Anticoagulants 30 (3.0) 4 (2.8) 26 (3.0) 6 (1.8) 2 (2.0) 4 (1.7) 
Dyslipidemic 
agents 
14 (1.4) 0 (0) 14 (1.6) 1 (0.3) 1 (1.0) 0 (0) 
Antidiabetics 12 (1.2) 2 (1.4) 10 (1.2) 12 (3.5) 3 (3.1) 9 (3.7) 
Antiasthmatics 7 (0.7) 0 (0) 7 (0.8) 7 (2.1) 3 (3.1) 4 (1.7) 
Peptic ulcer 
drugs 
40 (4.0) 2 (1.4) 38 (4.4) 22 (6.5) 7 (7.1) 15 (6.2) 
Laxatives 73 (7.2) 2 (1.4) 71 (8.2) 4 (1.2) 3 (3.1) 1 (0.4) 
Antidepressant
s 
3 (0.3) 1 (0.7) 2 (0.2) 4 (1.2) 2 (2.0) 2 (0.8) 
Sedatives 87 (8.6) 24 (17) 63 (7.3) 6 (1.8) 6 (6.1) 0 (0) 
Antipsychotics 22 (2.2) 3 (2.1) 19 (2.2) 1 (0.3) 0 (0) 1 (0.4) 
Antiseizure 13 (1.3) 0 (0) 13 (1.5) 3 (0.9) 2 (2.0) 1 (0.4) 
Antiparkinson’s 
drugs 
0 (0) 0 (0) 0 (0) 1 (0.3) 1 (1.0) 0 (0) 
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NSAIDs 78 (7.7) 25 (18) 53 (6.1) 125 (37) 6 (6.1) 119 (49) 
Other 
analgesics 
49 (4.9) 6 (4.3) 43 (5.0) 13 (3.8) 2 (2.0) 11 (4.6) 
Corticosteroids 32 (3.2) 0 (0) 32 (3.7) 4 (1.2) 3 (3.1) 1 (0.4) 
Antihistamines 1 (0.1) 0 (0) 1 (0.1) 0 (0) 0 (0) 0 (0) 
Electrolytes or 
fluids 
27 (2.7) 26 (18) 1 (0.1) 11 (3.2) 5 (5.1) 6 (2.5) 
Experimental 
drugs 
1 (0.1) 0 (0) 1 (0.1) 0 (0) 0 (0) 0 (0) 
Others 42 (4.2) 9 (6.4) 33 (3.8) 40 (12) 22 (22) 18 (7.5) 
 
ADEs, adverse drug events; NSAIDs, Non-steroidal antiinflammatory drugs. 
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Age (y)        
   <65 1304 203 (16) - - 149 (11) - - 










Gender        
   Female 1501 318 (21) - - 202 (13) - - 










Admitted ward        
   Medicine 1531 350 (23) - - 182 (12) - - 




















Doctor in charge        
   Not resident 
physician 
2526 499 (20) - - 205 (8) - - 
   Resident 
physician 












       
   Scheduled 1609 320 (20) - - 215 (13) - - 
   Emergency 
admission 










   Transferred 
from other ward 










History of allergy        
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   Absent 3117 640 (21) - - 368 (12) - - 












       
   <4 1532 316 (21) - - 138 (9) - - 










* Adjusted OR was calculated from multivariate logistic regression model with all 
listed variables. 
ADE, adverse drug event; ICU, intensive care unit; OR, odds ratio; CI, 
confidence interval; -, reference. 
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Table 5. Stages of primary errors associated with preventable and potential 












Preventable ADEs 49 (35) 0 (0) 0 (0) 15 (11) 77 (55) 
Intercepted 
potential ADEs 
88 (90) 0 (0) 6 (6) 4 (4) 0 (0) 
Nonintercepted 
potential ADEs 
182 (76) 2 (0.8) 2 (0.8) 49 (20) 6 (2) 
All above events 319 (66) 2 (0.4) 8 (2) 68 (14) 83 (17) 
ADEs, adverse drug events. 
 
 
